Cannabis, Pregnancy and Breastfeeding: What Mothers Deserve to Know About the Endocannabinoid System

Pregnancy can bring nausea, vomiting, pain, anxiety, insomnia and dramatic changes in appetite. For generations, some mothers have reported using cannabis to manage these symptoms—sometimes after conventional treatments failed or produced unwanted side effects.

That does not mean cannabis has been proven safe during pregnancy. It does mean the subject deserves something better than fear, stigma or oversimplified talking points.

The human body has its own endocannabinoid system, breast milk naturally contains endocannabinoids, and several studies—including a notable five-year study from Jamaica—have reported outcomes that complicate the claim that prenatal cannabis exposure inevitably causes developmental harm.

At the same time, THC is not identical to the cannabinoids produced by the human body, it can cross the placenta, and it can remain in breast milk for days or weeks. Current medical guidance therefore recommends avoiding cannabis during pregnancy and lactation.

The responsible conclusion is not that cannabis is harmless. It is that mothers deserve honest information, individualized medical care and significantly better research.

Why Some Mothers Turn to Cannabis

People report using cannabis during pregnancy for many of the same reasons other patients use it: nausea, vomiting, pain, sleep problems, anxiety and loss of appetite.

For someone experiencing severe morning sickness or hyperemesis gravidarum, the attraction is understandable. Being unable to keep down food, water or prenatal vitamins can itself become medically dangerous. Cannabis may also appear preferable to medications that cause sedation, dependence or other serious side effects.

However, patient-reported relief is not the same as proof of safety or effectiveness. Cannabis products vary widely in potency, cannabinoid content, contaminants and method of administration. Modern high-THC products may also be substantially stronger than the cannabis evaluated in older pregnancy studies.

Anyone who is pregnant, breastfeeding or trying to conceive should discuss symptoms and treatment options with a qualified healthcare professional. No prescribed medication should be abruptly discontinued without medical guidance.

Breast Milk Already Contains Cannabinoid-Like Compounds

One of the most interesting—and frequently misunderstood—parts of this conversation is the presence of endocannabinoids in human breast milk.

Endocannabinoids are signaling molecules made naturally by the body. They interact with cannabinoid receptors and help regulate functions including appetite, metabolism, pain, mood, immune activity and nervous-system development.

Researchers have identified both anandamide, also called AEA, and 2-arachidonoylglycerol, or 2-AG, in human milk. Studies are still examining how concentrations change during lactation and what roles these compounds may play. Animal research has led scientists to investigate whether endocannabinoid signaling contributes to suckling, appetite and energy regulation in newborns. Research published in Nutrients measured normal ranges of AEA and 2-AG in human milk, while a separate human-milk metabolome study described multiple components of the milk endocannabinoid system.

In that limited biological sense, breastfeeding already transfers cannabinoids—specifically, cannabinoids produced naturally by the human body.

But that fact should not be distorted into saying THC exposure is automatically safe. Anandamide, 2-AG and plant-derived THC are different molecules, appear at different concentrations and may activate cannabinoid receptors differently. The natural presence of endocannabinoids demonstrates that cannabinoid signaling is part of human biology; it does not establish a safe prenatal or infant dose of THC.

What the Jamaican Cannabis Studies Actually Found

A frequently cited piece of research followed mothers and children in rural Jamaica, where cannabis use was culturally established and some women used cannabis during pregnancy.

The original study, published in Pediatrics in 1994, evaluated newborns whose mothers used cannabis and compared them with non-exposed newborns. At three days, researchers reported no significant neurobehavioral differences associated with exposure. At one month, the exposed group received better scores on several measures, including autonomic stability, alertness, irritability and self-regulation. The original Jamaican neonatal study is indexed by the National Library of Medicine.

Researchers also followed 59 of the Jamaican children through age five. Approximately half had prenatal cannabis exposure, and exposed children were matched with non-exposed children based on factors including maternal age, parity and socioeconomic status.

Testing at ages four and five found no significant developmental differences attributable to prenatal cannabis exposure. The researchers instead found that aspects of the home environment were more strongly associated with developmental scores. Read the five-year follow-up abstract on PubMed.

These findings deserve recognition, but so do the limitations:

• The follow-up involved only 59 children.

• Cannabis potency and patterns of use differed from many products available today.

• An observational study cannot prove that an exposure is safe.

• Cultural practices, nutrition, family support and other environmental conditions may influence outcomes.

• Other studies have reported possible associations between prenatal exposure and birth or neurodevelopmental outcomes.

The Jamaican research does not prove that cannabis benefits fetal development. What it does show is that the science is more complicated than the claim that prenatal exposure must produce obvious developmental damage.

https://youtube.com/shorts/38TTOApyHvQ?feature=share

What the Broader Evidence Says

Cannabis research involving pregnancy is difficult because controlled trials intentionally exposing pregnant participants would be unethical. Researchers must therefore rely largely on observational studies.

That creates serious challenges. Maternal cannabis use can overlap with tobacco use, alcohol exposure, poverty, stress, inadequate prenatal care and other variables that independently affect birth and childhood outcomes. Researchers attempt to control for these factors, but they cannot always eliminate them.

Some modern studies have associated prenatal cannabis exposure with lower birth weight, premature birth, neonatal intensive-care admission or later behavioral and attention problems. These associations appear stronger with frequent use, although uncertainty remains about causation and residual confounding.

For these reasons, the American College of Obstetricians and Gynecologists currently advises against cannabis use during pregnancy and lactation. Its updated consensus also says that continued cannabis use is not, by itself, a contraindication to breastfeeding and that breastfeeding should not automatically be discouraged. Read ACOG’s clinical consensus.

That distinction matters. Supporting cessation does not require separating a mother from her healthcare provider, discouraging prenatal care or automatically denying an infant the established benefits of breastfeeding.

THC in Breast Milk Is Not the Same as Anandamide

Unlike the body’s short-lived endocannabinoids, THC is highly fat-soluble. It can accumulate in body fat and enter breast milk.

The National Library of Medicine’s LactMed database reports that THC has been detected in milk from approximately six days to more than six weeks after maternal use, depending on frequency, dose, individual metabolism and study methods. This means “pumping and dumping” for a few hours cannot reliably eliminate exposure.

LactMed also notes that older studies of occasional use did not detect clear effects in breastfed infants, but those studies were too limited to exclude long-term harm and involved cannabis that was generally less potent than many products sold today. Daily or near-daily exposure has raised greater concern, including a possible effect on motor development. Review the complete LactMed cannabis entry.

Mothers should also avoid smoking or vaping around an infant. Secondhand smoke, impaired caregiving and unsafe sleep practices can create risks independent of what passes through milk.

The Prescription-Drug Double Standard Deserves Scrutiny

Cannabis is often discussed as if it were the only maternity treatment with uncertainty or risk. It is not.

https://youtube.com/shorts/nDFYWcBQCac?si=dp3HY_RrCRR1NjVr

Pregnant patients may be prescribed opioids for pain, benzodiazepines for anxiety, antidepressants, anti-nausea medications, sleep aids and other drugs when a clinician determines that expected benefits outweigh potential risks. Some of these medications are medically necessary and can be lifesaving. Their risks should not be minimized—and patients should never stop them suddenly without professional care.

But their legal and pharmaceutical status does not make them harmless.

Prolonged prenatal opioid exposure can cause neonatal opioid withdrawal syndrome. Symptoms can include tremors, excessive crying, sleep disruption, vomiting, diarrhea and feeding difficulties. The CDC also associates opioid exposure or opioid-use disorder during pregnancy with poor fetal growth, premature birth, stillbirth and certain birth defects. See the CDC’s pregnancy and opioid guidance.

When opioids are combined with medications such as benzodiazepines, antidepressants or gabapentin, studies have found a further increase in neonatal-withdrawal risk. A large cohort study reported a 30% to 60% increase in withdrawal risk with several of these co-exposures. Read the cohort study in The BMJ.

This does not prove cannabis is safer than prescription medication. It demonstrates why treatment decisions must be based on comparative evidence rather than whether a substance comes from a pharmacy or a cannabis plant.

It would also be inaccurate to claim that doctors universally “push” addictive drugs on pregnant patients. Many clinicians work carefully to minimize medication exposure. Nevertheless, the healthcare system should be willing to examine why medications with documented dependence and withdrawal risks can be accepted under medical supervision while cannabis discussions are sometimes met with punishment instead of honest risk-benefit counseling.

Criminalization Can Make Maternal Health Worse

Fear of arrest, child-welfare investigations or losing custody can discourage mothers from disclosing cannabis use and seeking prenatal care. That does not protect families.

Pregnant patients should be able to speak honestly with healthcare providers without stigma. Screening should be used to connect families with care—not to punish them. Clinicians should discuss why the mother is using cannabis, whether safer and better-studied treatments are available, product potency, frequency, route of administration and other exposures.

If a patient cannot or will not stop, harm-reduction counseling remains more constructive than abandonment. That can include avoiding smoke exposure, never driving or bed-sharing while impaired, preventing accidental ingestion, avoiding contaminated products and reducing the frequency and potency of use while working with a healthcare professional.

The Bottom Line

The endocannabinoid system is involved in pregnancy, lactation, appetite and early development. Human breast milk naturally contains anandamide, 2-AG and other endocannabinoid-related compounds. That makes cannabinoid science highly relevant to maternal health—but it does not make plant-derived THC equivalent to the substances naturally produced by the body.

The Jamaican studies found no measurable developmental harm through age five attributable to prenatal cannabis exposure in their small sample. Those findings deserve to be discussed, not erased. They also deserve to be presented alongside their limitations and the broader body of research.

At present, no major medical organization considers cannabis proven safe during pregnancy. Mothers should not interpret this article as instructions to begin using cannabis or discontinue prescribed treatment.

What mothers can demand is evidence-based guidance, honest comparisons between cannabis and conventional drugs, freedom from stigma, and far more rigorous research.

Cannabis policy should be built on science—not fear, selective outrage or the assumption that a prescription label automatically makes every alternative more dangerous.

This article is for educational purposes only and is not medical advice. Anyone who is pregnant, breastfeeding or planning a pregnancy should consult a qualified healthcare professional before using cannabis, changing medications or stopping prescribed treatment.